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Abstract
Background: Coumarin group antibiotics, such as novobiocin,
coumermycin A1 and clorobiocin, are potent inhibitors of DNA
gyrase. These antibiotics have been isolated from various
Streptomyces species and all possess a 3-amino-4-hydroxy-
coumarin moiety as their structural core. Prior labeling experi-
ments on novobiocin established that the coumarin moiety was
derived from L-tyrosine, probably via a L-hydroxy-tyrosine (L-
OH-Tyr) intermediate. Recently the novobiocin gene cluster from
Streptomyces spheroides was cloned and sequenced and allows
analysis of the biosynthesis of the coumarin at the biochemical
level using overexpressed and purified proteins.
Results : Two open reading frames (ORFs), NovH and NovI,
from the novobiocin producer S. spheroides have been over-
expressed in Escherichia coli, purified and characterized for
tyrosine activation and oxygenation which are the initial steps in
coumarin formation. The 65 kDa NovH has two predicted
domains, an adenylation (A) and a peptidyl carrier protein
(PCP), reminiscent of non-ribosomal peptide synthetases. Purified
NovH catalyzes L-tyrosyl-AMP formation by its A domain, can be
posttranslationally phosphopantetheinylated on the PCP domain,
and accumulates the covalent L-tyrosyl-S-enzyme intermediate on
the holo PCP domain. The second enzyme in the pathway, NovI,
is a 45 kDa heme protein that functions as a cytochrome P450-
type monooxygenase with specificity for the tyrosyl-S-NovH acyl
enzyme. The product L-OH-tyrosyl-S-NovH was detected by
alkaline release and high performance liquid chromatography
analysis of radioactive [3H]L-OH-Tyr and by mass spectrometry.
Also detected was 4-OH-benzaldehyde, a retro aldol breakdown
product of L-OH-Tyr. The amino acid released was (3R,2S)-3-OH-
Tyr by comparison with authentic standards.
Conclusions: This work establishes that NovH and NovI are
responsible for the formation of a L-OH-Tyr intermediate that is
covalently tethered to NovH in novobiocin biosynthesis. Compa-
rable A^PCP/P450 pairs for amino acid L-hydroxylation are found
in various biosynthetic gene clusters, such as ORF19/ORF20 in
the chloroeremomycin cluster for tyrosine, CumC/CumD in the
coumermycin A1 cluster for tyrosine, and NikP1/NikQ in the
nikkomycin cluster for histidine. This phenomenon of covalent
docking of the amino acid in a kinetically stable thioester linkage
prior to chemical modification by downstream tailoring enzymes,
could represent a common strategy for controlling the partitioning
of the amino acid for incorporation into secondary metab-
olites. ß 2001 Elsevier Science Ltd. All rights reserved.
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1. Introduction
The coumarin group of antibiotics, such as novobiocin,
clorobiocin and coumermycin A1 (Fig. 1A), are secondary
metabolites from certain Streptomyces species and exert
their antibacterial activity by inhibition of the type II
DNA topoisomerase DNA gyrase [1^4]. These inhibitors
have a 3-amino-4-hydroxy-coumarin and a substituted de-
oxysugar noviose as a common core that is essential for
their biological activity. Clorobiocin di¡ers from novobio-
cin in that the methyl group at the C-8 of coumarin ring is
replaced by a chlorine atom, and the carbamoyl at the C-
3P of the noviose is substituted by a 5-methyl-2-pyrrolcar-
boxyl group. Coumermycin A1 contains two of the cou-
marin^noviose core joined by a 3-methyl-2,4-dicarboxyl
pyrrole linker and has the same substituted noviose as in
clorobiocin. Gyrase inhibitors, including the structurally
similar quinolones [5], block DNA replication, induce
1074-5521 / 01 / $ ^ see front matter ß 2001 Elsevier Science Ltd. All rights reserved.
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SOS repair systems and eventually cause bacterial cell
death. Previous kinetic and structural studies [3,4,6,7]
have shown that coumarin group antibiotics are compet-
itive inhibitors of ATP binding to the gyrase B subunit.
Substitution of a 3P-noviose carbamoyl (novobiocin) for a
5-methyl-2-pyrrolcarboxyl group (clorobiocin) results in
an enhanced inhibitory activity toward gyrase in vitro
[8]. Coumermycin A1, on the other hand, acting like a
novobiocin dimer, stabilizes a dimer form of the 43 kDa
fragment of GyrB [9]. Early labeling studies have estab-
lished that the substituted coumarin and the prenylated
benzoic acid moieties were derived from L-Tyr while the
noviose was from glucose [10^12]. Recently, insights into
the biosynthesis of novobiocin were obtained by the
sequencing of the nov gene cluster from Streptomyces
spheroides [13]. As shown in Fig. 1B, it is possible that
L-hydroxy-tyrosine (L-OH-Tyr) could be a common pre-
cursor of both substituted coumarin and benzoyl moieties.
An amide synthase responsible for joining these two moi-
eties has been puri¢ed and characterized very recently [14].
The de¢ned nov genes in the novobiocin cluster [13]
provide a chance to elucidate some key steps for novobio-
cin assembly in vitro. We focused on delineating the en-
zymes that create the coumarin ring sca¡old. In this work
we have investigated two adjacent open reading frames
(ORFs) in the nov cluster, NovH and NovI, to establish
their role in tyrosine activation and modi¢cation in the
coumarin-forming pathway. Sequence homology analysis
suggested NovH is related to amino acid activating mod-
ules of non-ribosomal peptide synthetases (NRPSs) in hav-
ing two predicted domains, an amino acid adenylating (A)
domain and an aminoacyl-tethering peptidyl carrier pro-
tein (PCP) domain [15^17]. The second protein, NovI, has
similarities to subclasses of cytochrome P450 monooxyge-
nases [13,18^20]. Here we report that NovH activates L-
Tyr and forms a tyrosyl-S-NovH acyl-S-enzyme that is the
substrate for regio and stereospeci¢c hydroxylation by
NovI to yield a L-OH-tyrosyl group still tethered on the
NovH PCP domain.
Fig. 1. (A) Chemical structures of coumarin group antibiotics isolated from Streptomycetes. The coumarin moiety in the natural products is highlighted
in red. (B) The substituted coumarin (ring B, red) and the 4-OH benzoyl moiety (ring A, aqua) in novobiocin were derived from L-Tyr based on earlier
labeling studies. L-OH-Tyr is proposed to be a common intermediate in these two biosynthetic pathways.
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2. Results
2.1. Expression and puri¢cation of S. spheroides NovH and
NovI in Escherichia coli
Two enzymes that may be responsible for the initial
steps in the biogenesis of the coumarin ring in novobiocin
were expressed and puri¢ed. NovH is a didomain NRPS
with a putative L-tyrosine speci¢c A domain and a C-ter-
minal PCP domain while NovI shows signi¢cant sequence
homology to cytochrome P450 hydroxylases. E. coli
BL21(DE3) cells harboring NovH expression constructs
grown at temperatures above 30‡C after induction yielded
only insoluble protein. To obtain soluble protein, cells
were cooled to 24‡C before induction with 50 WM of iso-
propyl L-D-thiogalactopyranoside (IPTG). A C-terminal
His6-tagged NovH was puri¢ed by nickel a⁄nity chroma-
tography in apo-form with a protein yield of 30 mg/l.
NovI was expressed as inclusion bodies when grown above
20‡C, but soluble protein was obtained by growing at
15‡C for 72 h without IPTG induction. NovI was puri¢ed
as an N-terminal His10-tagged fusion protein by nickel
chelate chromatography with a protein yield of 5 mg/l of
culture. Both proteins were puri¢ed to near homogeneity
with a correct molecular weight as judged by SDS^PAGE
(Fig. 2A). As shown in Fig. 2B, the UV^visible spectrum
of the puri¢ed NovI indicates that NovI was fully loaded
with the heme cofactor.
2.2. Characterization of NovH as a L-Tyr speci¢c didomain
NRPS to generate a L-tyrosyl-S-NovH intermediate
2.2.1. Posttranslational modi¢cation of PCP domain with a
PPTase
Protein sequence alignment indicated that the C-termi-
nal portion of NovH resembles a typical PCP domain in
NRPS systems with a conserved active site Ser561 sur-
Fig. 2. (A) Coomassie brilliant blue-stained 10% SDS^PAGE gel show-
ing NovH and NovI proteins puri¢ed by nickel chelate chromatography.
Lanes 1 and 4, molecular weight standards; lane 2, puri¢ed NovI; lane
3, puri¢ed NovH. (B) UV^visible spectrum of the puri¢ed NovI protein.
The NovI protein was isolated as a holo protein containing 1 equivalent
of heme cofactor based on the calculation with the extinction coe⁄cient
(O) for NovI protein and the heme cofactor of 0.061 and 0.055 WM31
cm31 at Vmax 279 and 416 nm, respectively.
Fig. 3. Schematic representation of the proposed functions of NovH. NovH isolated from E. coli needs to be primed by a PPTase with CoA to become
a holo-protein by installing a prosthetic P-pant group at the active site Ser561 on the PCP domain [13]. The A domain activates L-Tyr as L-tyrosyl-
AMP and then transfers the L-tyrosyl group to the HS-pant-PCP domain of NovH through thioester formation.
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rounded by a canonical sequence (549DVRSNFFE-
MGGNSILAVDL567) for posttranslational priming [13].
Puri¢ed NovH protein was assayed for covalent attach-
ment of a phosphopantetheinyl (P-pant) group by Sfp
[21], a phosphopantetheinyltransferase (PPTase) from sur-
factin synthetase from Bacillus subtilis (Fig. 3). Under the
assay conditions, Sfp rapidly (6 3 min) modi¢ed the
NovH with [3H]CoA as substrate (data not shown)
[21,22]. The percentage of P-pant incorporation was esti-
mated to be s 95% based on the speci¢c radioactivity of
[3H]CoA and the concentration of NovH. Thus, NovH
was puri¢ed as an apo protein from E. coli, typical for
other heterologously expressed NRPS PCP domains [23],
but could be converted fully to the holo-PCP form by Sfp
in vitro.
2.2.2. A domain selectivity of NovH
The A domain of an NRPS is expected to be bifunc-
tional, i.e. activation of the amino acid substrate and sub-
sequent ligation of aminoacyl-AMP to the downstream
holo-PCP domain, as depicted in Fig. 3. The activity of
the NovH A domain, aminoacyl adenylate formation, was
assayed by a substrate-dependent ATP^[32P]PPi exchange
reaction. The relative activities of the amino acid sub-
strates tested are displayed in Fig. 4. The NovH A domain
was selective for both the chirality of K-carbon and prop-
erties of the side chain group. Only L-Tyr served as a
competent substrate for the NovH A domain. While D-
Tyr, Gly, L-Trp, 3-methyl-L-Tyr, and (2S,3R)-L-OH-Tyr
were essentially inactive, L-Ala, L-Phe, 3-chloro-L-Tyr,
and p-bromo-DL-Phe had marginal activities with an ap-
parent kobs of 1.0^4.5% relative to L-Tyr (Fig. 4). The
kinetic parameters of the ATP^PPi exchange assays of
several amino acids are summarized in Table 1. Overall
the kcat/Km values agree well with the kobs measurements
shown in Fig. 4 with L-Tyr showing the highest activity
with a kcat and Km value of 15 min31 and 1.4 mM, re-
spectively. Compounds p-bromo-DL-Phe and L-Phe pos-
sessed a slightly smaller Km, but showed a dramatic re-
duced kcat value, indicating the importance of the para-OH
group of L-Tyr for catalysis. Substitution on the meta
position had an adversary e¡ect for both kcat and Km
and the bulkier methyl group rendered 3-Me-L-Tyr a
much worse substrate than 3-Cl-L-Tyr.
2.2.3. Auto-aminoacylation of NovH with [3H]Tyr
The above ATP^PPi exchange assay established that the
A domain of NovH can selectively activate L-Tyr as Tyr-
AMP. The ability of holo-NovH to ligate the activated L-
Tyr onto the thiol of the P-pant arm on the PCP domain
was assayed using [3H]L-Tyr as substrate. As shown in
Fig. 5A,B, SDS^PAGE and autoradiographic analysis in-
dicated ATP-dependent covalent loading of L-Tyr onto
NovH. Without pretreatment of NovH with Sfp, no liga-
tion of L-Tyr to NovH was observed, implying that L-Tyr
labeling was speci¢c to the PCP domain, and further re-
Fig. 4. Relative activity of several amino acids towards the A domain of NovH as assessed by ATP^[32P]PPi exchange assays. L-phenyl-Gly, L-p-OH-
phenyl-Gly, p-OH-phenyl-acetate, and p-OH-phenyl-pyruvate were also examined and all of them failed to show any detectable activity (data not
shown).
Table 1
Kinetic parameters of the ATP^[32P]PPi assays of NovH A domain
Substrate kcat (min31) Km (mM) kcat/Km Selectivity
L-Tyr 15.0 þ 0.3 1.39 þ 0.05 10.8 100
p-Br-DL-Phe 0.44 þ 0.03 0.84 þ 0.14 0.52 4.8
L-Phe 0.13 þ 0.01 0.89 þ 0.19 0.15 1.4
3-Cl-L-Tyr 0.23 þ 0.03 2.17 þ 0.34 0.11 1.0
3-Me-L-Tyr 0.083 þ 0.009 6.13 þ 0.74 0.014 0.13
Reactions for L-Tyr were carried out with 4 WM of NovH and termi-
nated after 8 min incubation at 24‡C. For incubations of L-Phe, p-bro-
mo-DL-Phe (p-Br-DL-Phe), 3-chloro-L-Tyr (3-Cl-L-Tyr), and 3-methyl-L-
Tyr (3-Me-L-Tyr), 12 WM of NovH was used and the reactions were al-
lowed to continue for 23 min at 24‡C. See Section 5 for details.
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inforcing the evidence that NovH was puri¢ed in the apo-
protein form. A time course of NovH covalent auto-ami-
noacylation is shown in Fig. 5C. Under the conditions
used for the assays, self-aminoacylation was a rather
slow process and it took V50 min to plateau at a ¢nal
stoichiometry of 0.55 equivalent of L-Tyr-S-NovH.
2.3. Characterization of NovI as a cytochrome P450
monooxygenase that hydroxylates L-tyrosyl-S-NovH in
a regio- and stereospeci¢c manner
2.3.1. Incubation of NovI with[3H]L-tyrosyl-S-NovH
As shown in Fig. 6, NovI was anticipated to function as
Fig. 5. Demonstration of self aminoacylation of NovH with [3H]L-Tyr depending on Sfp treatment and ATP. (A) Coomassie brilliant blue-stained 10%
SDS^PAGE gel of various reaction mixtures. Lane 1, molecular weight markers ; lane 2, control reaction without Sfp treatment; lane 3, control reaction
without adding ATP; lane 4, complete reaction. (B) Autoradiogram of this gel. (C) Time course of [3H]L-Tyr aminoacylation of holo NovH self-cata-
lyzed by the A domain. Radiolabeled substrate incorporation was measured by TCA precipitation of the proteins followed by liquid scintillation count-
ing. See Section 5 for detailed information.
Fig. 6. Schematic representation of the reaction e¡ected by the cytochrome P450 monooxygenase NovI. The putative substrates are L-tyrosyl-S-NovH
and molecular oxygen. While the substrate L-tyrosyl-S-NovH provides two electrons for a single round of the hydroxylation reaction, the other two
electrons needed to reduce the oxygen atom are provided by NADPH via two-electron transfer e¡ected by electron transfer proteins ferrodoxin (Fd)
and ferrodoxin reductase (Fd Red). The electron transfer route is from NADPHCFAD in Fd RedCFe^S center in FdCHeme in NovICoxygen.
Heterologous electron transfer proteins from spinach were used in this study because the S. spheroides electron transfer proteins for NovI have not yet
been identi¢ed.
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a cytochrome P450 monooxygenase that hydroxylates the
L-carbon of the tethered L-tyrosyl group on NovH. The
native electron donating proteins of S. spheroides are yet
to be cloned, so commercially available spinach ferredoxin
and ferredoxin reductase were used in the NovI incuba-
tions. In the incubation shown in Fig. 7B, a ratio of 4:1
for NovH:NovI was used and the incubation proceeded
for 2 h at 24‡C. No radioactive species other than starting
[3H]L-Tyr was detected in solution. To evaluate any prod-
uct covalently bound to NovH, compounds were released
from NovH by KOH treatment to hydrolyze the amino-
acyl-S-PCP thioester linkage and analyzed by reverse-
phase high performance liquid chromatography (RP-
HPLC) and scintillation counting. The radioactivity of
fractions (1 ml in size) was plotted versus retention time
(rt) to give Fig. 7B, while Fig. 7A shows the analysis of the
identical reaction carried out in the absence of NovI. The
released radioactive compound (rt = 21.5 min) from the
control reaction (Fig. 7A) was identi¢ed to be [3H]L-Tyr,
as established by co-injection (data not shown). In the
reaction containing NovI, a much smaller substrate L-
Tyr peak (rt = 21.5 min) was presented, however, two
new peaks with rts of 7.8 and 25.8 min were observed
(Fig. 7B). The identity of ¢rst radioactive peak (rt = 7.8
min) was initially established as L-L-OH-Tyr by co-elution
with unlabeled authentic L-OH-Tyr added as carrier and
monitored by UV (at 230 nm). In addition to the 7.8 min
L-OH-Tyr peak, the HPLC UV chromatogram also de-
tected another product peak that co-eluted with the 25.8
min radioactive peak, indicating this UV-active peak was
likely derived from the added non-labeled carrier L-OH-
Tyr. The KOH treatment during chemical release of the
covalently tethered compound could promote a retro aldol
reaction breaking down L-OH-Tyr to 4-OH-benzaldehyde,
a process illustrated in Fig. 7C. Since the tritium label is at
positions 3 and 5 of the phenyl ring of the input substrate
[3H]L-Tyr, the L-OH-Tyr breakdown product 4-OH-benz-
aldehyde will be tritiated. Co-injection of the incubation
products with authentic 4-OH-benzaldehyde (Sigma) con-
¢rmed the comigration of the 25.8 min radioactive peak
(data not shown).
A large-scale incubation with 60 nmol of NovH allowed
isolation of enough products for mass characterization.
The two product peaks were collected following RP-
HPLC separation, lyophilized and subjected to matrix-as-
sisted laser desorption ionization time-of-£ight mass spec-
troscopy (MALDI-TOF MS) analysis. The measured
masses of 198.1 and 122.1 (M+H mode) matched well
with the predicted values of L-OH-Tyr (C9H11NO4, calc.
197.1) and 4-OH-benzaldehyde (C7H6O2, calc. 122.0).
2.3.2. Properties of the NovI mediated hydroxylation
reaction
To see if product formation catalyzed by NovI is pro-
portional to the amount of substrate used, a series of in-
cubations with varying amounts of [3H]L-tyrosyl-S-NovH
were performed and analyzed. A linear correlation of the
amounts of product (L-OH-Tyr plus the breakdown prod-
uct 4-OH-benzaldehyde) and the substrate protein NovH
was observed (Fig. 8A).
As shown in Fig. 8B, when the amount of NovH was
¢xed at 3.1 nmol, and NovI was titrated down from 240 to
12 pmol, multiple turnovers on NovI were observed. At
the 12 pmol lower limit, NovI displayed up to 55 turn-
overs towards its partner substrate protein L-Tyr-S-NovH.
This result clearly demonstrates that NovH and NovI re-
Fig. 7. HPLC separation and identi¢cation of [3H]L-tyrosyl-S-NovH/
NovI incubation products released by KOH treatment. At the end of in-
cubation, the proteins were precipitated with 10% TCA and the protein
pellets was washed with water to remove soluble small molecules. Then
0.1 M KOH was added to redissolve protein pellets and the resultant
solution was incubated for 5 min at 60‡C to hydrolyze the aminoacyl
thioester linkage to NovH. Fractions (1 ml) from the RP-HPLC separa-
tion were collected and the radioactivity was measured by liquid scintil-
lation counting. See Section 5 for detailed conditions. (A) Plot of radio-
activity of the fractions versus rt (or fraction number) from the RP-
HPLC analysis of the control reaction in which NovI was withdrawn.
The released radioactive compound (rt = 21.3 min) was proven to be
[3H]Tyr by co-injection. (B) Plot of radioactivity of fractions versus rt
from the RP-HPLC analysis of the complete reaction. While there still
remained a small [3H]Tyr peak, the ¢rst new radioactive peak (rt = 7.2
min) co-eluted with L-OH-Tyr and the second new radioactive peak had
the same rt as 4-OH-benzaldehyde. (C) Schematic illustration of 4-OH-
benzaldehyde formation from hydroxylated product L-OH-Tyr via a ret-
ro aldol reaction promoted by KOH. Since the tritium label is on the
phenyl ring of the substrate L-Tyr, the breakdown product 4-OH-benzal-
dehyde is radioactive.
CHBIOL 74 18-4-01 Cyaan Magenta Geel Zwart
306 Chemistry & Biology 8/4 (2001) 301^312
constitute a competent enzymatic system for L-OH-tyro-
syl-S-NovH formation.
2.3.3. Determination of the stereochemistry of the new
chiral center at the L-carbon of the tyrosyl moiety of
L-Tyr-S-NovH
Although the newly generated chiral center of L-OH-
Tyr is lost at a later stage in coumarin biosynthesis (Fig.
1), it is still of interest to examine if the hydroxylation
reaction e¡ected by NovI is stereospeci¢c and to establish
the absolute stereochemistry. As shown in Fig. 9, the RP-
HPLC-puri¢ed NovI product, [3H]L-OH-Tyr, had the
same rt (18.4 min) as chemically prepared (2S,3R)-L-OH-
Tyr (Fig. 9, trace C versus trace A) when analyzed by
chiral HPLC (Daicel ChiralPAK WH0) [24,25]. Under
the operating conditions, the (2R,3S) isomer (rt = 9.8
min) was well resolved from the (2S,3R) isomer (Fig. 9,
trace B). Chiral HPLC analysis clearly indicated that
the newly generated chiral center is an R center and that
NovI makes a (2S,3R)-3-OH-Tyr-S-NovH covalent acyl
enzyme.
3. Discussion
The results reported in this work establish enzymatic
activities for the two proteins NovH and NovI from the
novobiocin biosynthetic cluster and showed that amino-
acylated NovH is a hydroxylation substrate for NovI.
The bioinformatic-based predictions of an A and PCP
domain in NovH [16] were validated with the puri¢ed
enzyme. The A domain is speci¢c for L-tyrosine, as as-
sessed by an amino acid-dependent ATP^[32P]PPi ex-
change assay which monitors reversible formation of ty-
rosyl-AMP. The apo-PCP domain of NovH must be
primed by covalent posttranslational phosphopantetheiny-
lation. A dedicated PPtase for the nov cluster has not yet
been identi¢ed so we used the broad speci¢city PPTase Sfp
from the surfactin synthetase cluster of Bacillus [21]. The
capture of the L-tyrosyl-AMP by the holo HS-pant-PCP
domain of NovH was established by SDS^PAGE and tri-
chloroacetic acid (TCA) precipitation assay with [3H]L-ty-
Fig. 9. Determination of the stereochemistry of the new chiral center in L-OH-tyrosyl moiety introduced by NovI by chiral HPLC with ChiralPAK
WH0 from Daicel. Isocratic elution with 2.5 mM CuSO4 at 1 ml/min was used and the UV detector was set at 272 nm. Trace A, HPLC chromatogram
of chemically prepared authentic (2S,3R)-L-OH-Tyr [24]. Trace B, HPLC chromatogram of chemically prepared racemic threo isomers, (2S,3R) and
(2R,3S) L-OH-Tyr [29]. The left Y-axis in mAU is for trace A and B. Trace C: plot of radioactivity of fractions (0.5 ml in size) versus rt from the anal-
ysis of the enzymatic product [3H]L-OH-Tyr by chiral HPLC. [3H]L-OH-Tyr was excised from NovH and isolated from RP-HPLC by collecting the 7.8
min peak (Fig. 7B). The right Y-axis in dpm is for plot C.
Fig. 8. (A) Total product formation ([3H]L-OH-Tyr plus [3H]4-OH-benz-
aldehyde) was proportional to the amount of NovH used. (B) NovI
functioned catalytically in the reaction and up to 55 turnovers were ob-
served under the conditions described in Section 5.
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rosine to detect and quantitate the mole fraction of NovH
accumulating as L-tyrosyl-S-NovH.
When the proposed companion protein NovI was puri-
¢ed it was red and contained one equivalent of heme co-
factor. When provided with a heterologous electron donor
system, spinach ferredoxin reductase and ferredoxin (the
S. sphaeroides electron transfer proteins are yet to be
cloned), to transfer electrons from NADPH, NovI utilized
O2 and performed as a catalytic monoxygenase. Initial
assays indicated that NovI would not oxygenate free tyro-
sine or the soluble thioester surrogate L-tyrosyl-S-N-acetyl
cysteamine (data not shown). Thus, NovI recognizes the L-
tyrosyl moiety presented on the pantetheinyl arm of the
PCP domain of NovH. NovI acts catalytically on its ty-
rosyl-S-NovH partner but the L-OH-Tyr product stays
covalently tethered on the NovH PCP domain. To identify
the L-OH-K-amino acid product, KOH was added to
cleave the thioester linkage and thus allowed determina-
tion of the identity and stereochemistry of the L-hydrox-
ylation product.
The question arises why NovI is speci¢c for hydroxyla-
tion of the benzylic carbon of tyrosine tethered as a thio-
ester on a partner protein. One answer comes from inspec-
tion of the structure of the coumarin ring B moiety of
novobiocin. The coumarin is a two-ring lactone and the
mechanism of lactonization has been inferred by 18O label-
ing studies to be attack of the carboxyl oxygen on the aryl
ring of Tyr in an oxidative cyclization [11]. However, 18O
enrichment of the ring oxygen was quite low (V0.078 at%
excess) in that study and we favor a distinct pathway of
lactonization, based on our enzymatic results and putative
functions of other ORFs in the nov cluster. Here we pro-
pose that the ring oxygen likely arises from hydroxylation
by a predicted £avoprotein monoxygenase NovC (Fig. 10).
Lactone formation would then arise by intramolecular
capture of the proposed 2,4-dihydroxy-3-methyl-L-keto-
Tyr-S-PCP of NovH as shown in Fig. 10. This is closely
analogous to the intramolecular lactonizing step in 6-de-
oxyerythronolide biosynthesis [26] and in fengycin [27]
biosynthesis by polyketide synthase (PKS) and NRPS as-
sembly lines, respectively. The thermodynamic activation
of the thioester moiety makes the cyclization and release
from ACP/PCP carrier domains a favorable chain release
step. The same logic applies for release of the coumarin
from NovH.
This logic for coumarin ring assembly suggests the PCP
domain of NovH is a sca¡old on which the L-tyrosyl moi-
ety is ¢rst covalently docked in kinetically stable but ther-
modynamically activated thioester linkage, and then
chemically modi¢ed before cyclization. The pantetheinyl
arm is 20 Aî long if fully extended and this property may
be crucial for providing access to the enzymes that will
modify the tyrosyl backbone and ring. The ¢rst of these
modi¢cations is now proven to be the L-hydroxylation by
NovI. Restriction of NovI activity to a tyrosine covalently
tethered to the NovH PCP rather than free tyrosine may
have advantages to the antibiotic-producing cell. It would
control the fraction of the cellular pool of tyrosine that is
hydroxylated and diverted to novobiocin formation. The
companion ORFs to NovH and NovI include NovJ and
NovK, predicted L-ketoacyl-carrier protein reductases
[13], NovC, the proposed aromatic ring hydroxylating £a-
Fig. 10. Schematic illustration of the proposed pathway of aminocoumarin formation in the biogenesis of novobiocin. The functions of NovH and
NovI have been established in this study. Both NovJ and NovK are similar to 3-keto-ACP reductase and they may form a heterodimer and operate in
the reverse direction to oxidize 3-OH to 3-keto. NovO is similar to some quinone C-methyltransferases [30,31] but the timing of methylation is not
clear. NovC resembles £avin-dependent monooxygenases (35 and 32% similarity to dimethylaniline and cyclohexanone monooxygenases, respectively)
[32,33], and is proposed to hydroxylate the ortho position of the phenyl ring. The nucleophilic attack of the ortho hydroxyl group on the thioester car-
bonyl center would release the coumarin ring and regenerate NovH.
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voprotein, and NovO, a predicted SAM-dependent C-
methyltransferase [13]. The action of these three enzymes
on L-OH-Tyr-S-NovH, as suggested in Fig. 10, would
produce the 2,4-dihydroxy-3-methyl-L-keto-tyrosyl-S-
NovH acyl-S-enzyme. Its intramolecular cyclizative cap-
ture would regenerate free NovH and yield the released
lactone that is the coumarin ring found as the sca¡old in
the coumarin group antibiotics. NovJ could act alone to
oxidize the L-hydroxyl group, but it is also possible that
NovJ and NovK are subunits of single dimeric enzyme or
represent two di¡erent isoenzymes. A comparable pair
BbsC/BbsD, similar to 3-hydroxyacyl-CoA dehydrogen-
ases, has been implicated in the L-oxidation of benzylsuc-
cinate [28]. The timing of NovC and NovO action is as yet
unknown, but our result that 3-methyl-L-Tyr was a very
poor substrate for NovH (Table 1) argues that NovO acts
downstream of NovH and NovI. The proposed pathway
here would represent a novel use of the NRPS-type amino-
acyl covalent tethering strategy and suggests that four tai-
loring enzymes, NovI, J/K, C and O, carry out sequential
modi¢cation of a tyrosyl-S-pantetheinyl acyl enzyme.
In terms of maximizing metabolic economy it is possible
that the L-OH-Tyr-S-NovH is also the source of the ring
A 4-OH-benzoyl moiety of novobiocin. With the enzymi-
cally generated L-OH-Tyr and also with authentic samples
we have seen facile retro aldol fragmentation across the
C2^C3 bond to produce 4-OH-benzaldehyde and glycine.
Oxidation of this aldehyde to the acid, perhaps after pre-
nylation, could be e¡ected by an oxidase to provide the
ring A fragment of novobiocin.
Finally, a data base search for pairs of ORFs homolo-
gous to NovH and NovI that are found clustered together,
reveals two other candidates, besides the pair in coumer-
mycin A1 CumC/CumD [18], that could analogously be
activating amino acids as P-pant thioesters and then car-
rying out L-hydroxylation. One pair is ORF19 and ORF20
in the chloroeremomycin biosynthetic cluster [19], which is
predicted to be a comparable A^PCP/P450 pair and this
glycopeptide antibiotic of the vancomycin family indeed
has a heptapeptide sca¡old with (3R)-L-OH-Tyr residues
at positions 2 and 6 [19]. In the biosynthetic cluster for the
nucleoside antibiotic nikkomycin there is a corresponding
A^PCP/P450 pair predicted, NikP1/NikQ, and we would
assign NikQ as likely to be a monooxygenase producing a
L-OH-His-S-PCP acyl-S-enzyme intermediate. It will be of
interest to validate these predictions and see if NovI,
CumD, ORF20 and NikQ do indeed form a new subgroup
of cytochrome p450 monoxygenases committed to L-hy-
droxy amino acid formation on a segregated amino acid
pool tethered to the PCP domains of partner proteins.
4. Signi¢cance
The antibacterial agents novobiocin, clorobiocin and
coumermycin A1 all contain a 3-amino-4-hydroxy-cou-
marin moiety that is a central sca¡old for presentation
of these antibiotics to their target, the N-terminal portion
of the GyrB subunit of DNA gyrase. The biosynthesis of
the bicyclic coumarin platform has been known to occur
from tyrosine and presumably proceed through a L-OH-
Tyr intermediate. The recent sequencing of the biosyn-
thetic gene cluster for both novobiocin, and more recently,
coumeromycin A1, has suggested that two proteins, NovH
and NovI, would start the coumarin pathway and repre-
sent the ¢rst committed steps to tyrosyl L-hydroxylation.
This work validates that the tyrosine molecules for cou-
marin ring formation are activated and tethered as cova-
lent tyrosyl-S-NovH acyl enzyme species on the PCP do-
main of NovH, and that this tyrosine pool is the speci¢c
substrate for the partner enzyme NovI, a cytochrome P450
monooxygenase. The L-OH-Tyr-S-NovH product from
NovI action is proposed to be a substrate for oxidation,
cyclization and concomitant release of the 3-amino-4-hy-
droxy-coumarin from the NovH PCP domain. Homologs
of the NovH/NovI pairs, found in other microorganisms
that produce antibiotics containing L-hydroxyl amino acid
moieties, such as the vancomycins and nikkomycins, sug-
gest the hydroxylation of a tethered aminoacyl-S-PCP
may be a general strategy for diversion of a fraction of
the amino acid pool to modi¢cations that provide building
blocks for antibiotic biosynthesis.
5. Materials and methods
5.1. Cloning of novH and novI genes
The novH and novI genes of the novobiocin cluster were am-
pli¢ed from S. spheroides (ATCC26935) genomic DNA by poly-
merase chain reaction. Primers NovH-NtermNdeI (5P-GGA
AGG CAT ATG TTC AAC ACT CGT GCG AAC AA-3P)
and NovH-CtermXhoI (5P-GCC TTC CTC GAG CTC CTC
CAG GGT CGC TAT-3P) were used to amplify the novH gene.
The novI gene was ampli¢ed with primers NovI-NtermNdeI (5P-
CCG ATA CAT ATG AGC ACC CGT CCG ACC GTG-3P) and
NovI-NtermXhoI (5P-GGG TAA CTC GAG GCC CGT GAT
CCT GAT CGG-3P). The introduced NdeI and XhoI restriction
sites of each primer are highlighted with boldface type. The am-
pli¢ed products were gel-puri¢ed, digested with NdeI and XhoI
restriction enzymes, and ligated into pET24b and pET16b to give
NovH C-terminal His6-tagged and NovI N-terminal His10-
tagged constructs, respectively. The resulting plasmids, pHC10
and pHC21, were transformed into E. coli BL21(DE3) for protein
overexpression.
5.2. Overexpression and puri¢cation of NovH and NovI proteins
Cells harboring pHC10 plasmid were grown in LB medium
supplemented with 40 Wg/ml kanamycin. The cells were grown
at 37‡C to an OD600 of 0.6, cooled to 24‡C, induced with 50
WM of IPTG and allowed to grow for an additional 6 h at
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24‡C. Growth of pHC21/BL21(DE3) involved inoculating 1 l of
LB medium containing 100 mg ampicillin, 50 mg FeCl3 and 50
mg N-aminolevulinic acid with 10 ml of overnight culture, and
was continued for 3 days at 15‡C without IPTG induction. The
cells from each 6U1 l culture were harvested by centrifugation
(10 min at 6000Ug) and resuspended in 70 ml of bu¡er A (20
mM Tris^Cl, 0.2 M NaCl, 5 mM imidazole, pH 8.0). Resus-
pended cells were broken by French Press (two passages at
15 000 psi) and the cell debris was removed by centrifugation
(30 min at 35 000Ug). The supernatant was incubated with 4 ml
of super£ow nickel resin (Qiagen) for 2 h at 4‡C. The resin
was then packed into a column, washed with 20 bed volumes
of wash bu¡er (bu¡er A plus 20 mM imidazole), and the protein
was eluted by a linear gradient of 20^150 mM imidazole. Frac-
tions containing the protein (judged by SDS^PAGE) were
pooled, dialyzed against bu¡er B (20 mM Tris^Cl, 50 mM
NaCl, 1 mM dithiothreitol, 10% glycerol, pH 7.5), concentrated,
£ash frozen in liquid nitrogen and stored at 380‡C. Concentra-
tions of the puri¢ed NovH and NovI were measured spectropho-
tometrically at 280 nm using the calculated extinction coe⁄cient
of 0.031 and 0.061 WM31 cm31 for NovH and NovI, respectively.
5.3. Posttranslational modi¢cation of the NovH PCP domain with
Sfp
A TCA precipitation assay [22] was adopted to measure the
time course and the stoichiometry of the apo to holo conversion
of NovH using B. subtilis PPTase enzyme Sfp. Reactions (200 Wl,
in duplicate) contained 75 mM Tris^Cl (pH 7.5), 5 mM MgCl2,
10 mM Tris-(2-carboxyethyl)phosphine (TCEP; Sigma), 50 WM
[3H]CoA (74 Ci/mol, DuPont NEN), 3.7 WM NovH and 0.3 WM
of Sfp. Samples of 15 Wl were withdrawn at various time points,
and quenched with 0.5 ml of 10% TCA. The precipitated protein
was pelleted, washed with 10% TCA, redissolved in 0.5 ml of 88%
formic acid, and counted for radioactivity. Percent modi¢cation
of NovH was calculated from the speci¢c activity of the [3H]CoA
and the NovH concentration.
5.4. ATP^[32P]PPi exchange assay for A domain activity
Reactions (100 Wl) containing 75 mM Tris^Cl (pH 7.5), 5 mM
MgCl2, 5 mM TCEP, 2 mM ATP, 1.5 mM of amino acid sub-
strate, 4 WM of NovH, and 1 mM [32P]pyrophosphate (3.6 Ci/
mol, DuPont NEN) were carried out at 24‡C. The reactions were
initiated by the addition of NovH and allowed to proceed for 25
min (5 min for L-Tyr), and then quenched with charcoal suspen-
sions (500 Wl of 1.6% (w/v) activated charcoal, 4.5% (w/v) tetra-
sodium pyrophosphate, and 3.5% perchloric acid in water). The
charcoal was pelleted by centrifugation, washed twice with
quenching bu¡er without added charcoal, and then resuspended
in 0.8 ml of water and submitted for liquid scintillation counting.
The amount of bound radioactivity was converted to reaction
rate using the speci¢c radioactivity of the [32P]pyrophosphate.
To determine kinetic parameters of L-Tyr, reactions were carried
out at 24‡C in a total volume of 100 Wl that contained 75 mM
Tris^Cl (pH 7.5), 5 mM MgCl2, 5 mM TCEP, 2 mM ATP, 4 WM
NovH and 1 mM [32P]pyrophosphate, and various amounts of L-
Tyr. The reactions were terminated after 8 min incubation. For
incubations of L-Phe, 3-Cl-L-Tyr, p-Br-DL-Phe, and 3-Me-L-Tyr,
12 WM of NovH was used and the reactions were allowed to
continue for 23 min at 24‡C.
5.5. Covalent aminoacylation of L-Tyr on the PCP domain of
NovH
5.5.1. Autoradiography demonstrating auto-aminoacylation of
[3H]L-Tyr to NovH
NovH was ¢rst primed with Sfp to install the P-pant group on
the PCP domain. The incubation mixture (50 Wl) included 75 mM
Tris^Cl (pH 7.5), 5 mM MgCl2, 0.1 mM [3H]Tyr (1 Ci/mmol,
Dupont NEN), 5 mM TCEP, 2 mM ATP and 50 WM of NovH.
The reaction was allowed to proceed for 30 min at 24‡C and 8 Wl
was used for electrophoreses on 10% SDS^PAGE. Control reac-
tions were carried out in parallel in which either the ATP was
omitted or NovH was used without Sfp treatment. For visual-
ization, the gel was stained with Coomassie brilliant blue solu-
tion, destained and soaked in Amplify (Amersham) for 15 min.
The dried gel was exposed to ¢lm for 24 h before developing.
5.5.2. TCA precipitation assay
TCA precipitation assays were performed to measure the time
course and the stoichiometry of auto-aminoacylation of L-Tyr by
NovH. Reactions of 100 Wl in volume contained 75 mM Tris^Cl
(pH 7.5), 5 mM MgCl2, 5 mM TCEP, 0.5 mM CoA, 0.2 WM Sfp,
10 WM NovH, 0.5 mM [3H]L-Tyr (90 Ci/mol) and 3 mM ATP,
and incubated for 30 min at 24‡C to allow the phosphopantethei-
nylation prior to initiation by the addition of ATP. Aliquots of
10 Wl were withdrawn at various time points, quenched with 0.5
ml of 10% TCA, and the precipitated protein was pelleted,
washed and counted for radioactivity. Percent auto-aminoacyla-
tion was calculated from the speci¢c activity of the [3H]L-Tyr and
the NovH concentration.
5.6. Incubation of NovI with L-tyrosyl-S-NovH
Holo NovH was loaded with [3H]L-Tyr at 24‡C for 1.5 h in a
reaction mixture (200 Wl) that contained 75 mM Tris^Cl (pH 7.5),
5 mM MgCl2, 0.5 mM [3H]L-Tyr (90 Ci/mol), 3 mM ATP, 2 mM
TCEP and 40 WM NovH. Then NADPH, spinach ferredoxin
(Sigma), ferredoxin reductase (Sigma), and NovI were added to
a ¢nal concentration of 1.5 mM, 5 WM, 0.1 U and 10 WM, re-
spectively. Incubation was allowed to continued for 2 h at 24‡C
prior to quenching with 1 ml of 10% TCA. The precipitated
proteins were pelleted by centrifugation, washed three times
with 1 ml water, and redissolved in 100 Wl of 0.1 N KOH solu-
tion. The tethered product was released from the carrier protein
by incubating for 5 min at 60‡C. Routinely, a small amount of
authentic non-labeled (2S,3R)-L-OH-Tyr (a gift from Dr. Man-
jinder S. Lall and Dr. Dale L. Boger of the Scripps Research
Institute) [24] was added during the work-up as a non-labeled
carrier compound. The proteins were removed by acidifying the
mixture with 5 Wl of 50% TFA followed by centrifugation. Prod-
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uct formation was analyzed by HPLC using a Vydac1 C18 small
pore analytical column (5 Wm, 4.6U250 mm) at 1 ml/min £ow
rate with monitor setting at 230 nm. The elution pro¢le started
with 100% solvent A (A = H2O, 0.1% TFA) for 10 min, followed
by a linear gradient from 0 to 50% solvent B (B = acetonitrile,
0.1% TFA) over 15 min. The radioactivity of fractions (1 ml) was
measured by liquid scintillation counting of the collected samples.
Plots of radioactivity versus fraction number were used to deter-
mine the rt of the product. A control incubation was carried out
in parallel under the same conditions except that NovI was omit-
ted.
5.7. Mass analyses of the NovI reaction products released from
NovH
A large-scale incubation (2 ml) contained 75 mM Tris^Cl (pH
7.5), 50 mm NaCl, 5 mM MgCl2, 3 mM ATP, 5 mM TCEP, 1.5
mM NADPH, 1 mM L-Tyr, 40 WM of holo NovH, 5 WM NovI,
5 WM ferredoxin and 0.4 U ferredoxin reductase. Incubation pro-
ceeded for 1 h at 24‡C for aminoacylation of NovH with L-Tyr
prior to the addition of NovI, NADPH and the electron transfer
proteins to initiate hydroxylation. The work up procedure noted
above for radioactive incubations was followed. Two peaks that
possessed the same rt as the (2S,3R)-L-OH-Tyr and 4-OH-benz-
aldehyde (Sigma) standards were collected from RP-HPLC,
lyophilized and subjected to MALDI-TOF MS analysis.
5.8. Properties of the NovI mediated hydroxylation reaction
To examine whether NovI catalyzed product formation in a
substrate-dependent fashion, a series of incubations (200 Wl)
were carried out. Incubation mixtures contained 75 mM Tris^
Cl (pH 7.5), 5 mM MgCl2, 0.5 mM [3H]L-Tyr (90 Ci/mol),
2 mM ATP, 2 mM TCEP, 1 mM NADPH, 5 Wm ferredoxin,
0.1 U ferredoxin reductase, 10 WM NovI, and various concentra-
tions (5^80 WM) of the holo NovH. After covalent loading of
L-Tyr achieved by incubating at 24‡C for 1.5 h, NovI and other
necessary components were added to initiate the L-hydroxylation
reaction. Reactions were terminated after 2 h at 24‡C with 10%
TCA. Work up and product analysis followed the procedure
described above. In another experiment, catalytic amounts (rang-
ing from 0.048 to 0.96 WM in 250 Wl of reaction mixture) of NovI
were used in the incubations while the concentration of NovH
was kept at 12.4 WM. Reactions were worked up and analyzed
after 4 h incubation at 24‡C.
5.9. Determination of the chirality of the L-OH center introduced
by NovI
An incubation was carried out to prepare [3H]L-OH-Tyr fol-
lowing procedures described above. The pure product was ob-
tained by RP-HPLC separation followed by lyophilization. The
stereochemistry of the L center was established by chiral HPLC
analysis with a ChiralPAK WH0 column (Daicel) compared with
chemically prepared reference samples of (2S,3R)-3-OH-Tyr [24]
and racemic threo isomers (2S,3R)- and (2R,3S)-3-OH-Tyr [29].
Isocratic elution at 1 ml/min £ow rate of 2.5 mM CuSO4 was
used. Fractions (0.5 ml) were collected and measured for radio-
activity by a liquid scintillation counter to determine the rt of the
enzymatic product. When analyzing unlabeled reference com-
pounds, their rts were measured by monitoring at 272 nm with
an UV-detector.
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